Frontlight ResearchEarly access
CompletedNo phase
Study to Evaluate the Efficacy and Safety of CM310 in Subjects With IgG4-related Disease
Key facts
- Who runs it
- Beijing Friendship Hospital
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 20 people enrolled
- Started
- 20 Feb 2023
- Ended
- 23 Apr 2024
- Type of study
- Interventional
- Treatments tested
- CM310
- Record updated
- 18 November 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (7)Hide the full registry criteria
Who can take part
- ≥18 years, male and female
- With IGG4-related disease
Who cannot take part
- Inoculate live vaccine within 4 weeks before screening
- Treponema pallidum antibody positive in screening period
- With a history of solid organ or cell transplantation within 6 months before screening
- Active hepatitis in screening period
- With other medical or non-medical conditions that are not suitable for the study by the investigator
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study is a single-arm study initiated to evaluate the efficacy and safety of CM310 in subjects with recurrent IgG4-related disease.
The group in the trial
- CM310Treatment being tested
CM310, subcutaneous
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Efficacy of an Anti-IL-4Ra as an add-on Therapy in Patients With Relapsed IgG4-related Disease: A Single-arm, Single-centre Clinical Study
- Record updated
- 18 November 2026